Condition
Chronic Hepatitis C Genotype 1
Total Trials
3
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
67%
2 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
P 2 (1)
P 3 (1)
P 4 (1)
Trial Status
Completed3
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT04246723Phase 2CompletedPrimary
Efficacy and Safety of All-Oral Combination of Narlaprevir/Ritonavir and Sofosbuvir in Treatment-naïve Patients With Chronic Hepatitis C Genotype 1
NCT01425203Phase 3CompletedPrimary
The Effect of Boceprevir in Russian Participants Diagnosed With Chronic Hepatitis C Genotype 1 (P08160)
NCT00910975Phase 4CompletedPrimary
Individualized Duration of Peg-interferon/Ribavirin Treatment of Hepatitis C
Showing all 3 trials